Ventus Therapeutics Announces Publication in Journal of ...

The article summarizes the historic difficulties of targeting inflammasome proteins for the treatment of several diseases of high unmet need.

Latest News | Ventus Therapeutics

Ventus Therapeutics Announces Publication in Journal of Experimental Medicine Describing Advances in Structure-based Drug Discovery for Inflammasome Targets.

Ventus Therapeutics no LinkedIn: #powerofresolution

Sharing our publication in the Journal of Experimental Medicine on “Advances toward structure-based drug discovery for inflammasome targets.” Learn how…

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor.

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor.

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor. 25 ...

Ventus launches to drug inflammasomes and more - ACS Publications

Ventus Therapeutics has launched with $60 million in series A financing from Versant Ventures and GV, the former Google Ventures, to develop small-molecule ...

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

D., Senior Vice President of Global Drug Discovery at Novo Nordisk. “This trial initiation marks the first stage in our NLRP3 inhibitor clinical ...

Board of Directors - Ventus Therapeutics

Our team includes experienced biopharmaceutical executives, scientists, and drug developers who have delivered multiple approved medicines, and luminary ...

Ventus Therapeutics | C&EN Global Enterprise - ACS Publications

The innate immune system is our first line of defense against microbial invaders, and a protein called NLRP3 is one of its loudest alarms.

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor.

Ventus Therapeutics annonce la publication d'un article dans le ...

Ventus Therapeutics annonce la publication d'un article dans le Journal of Experimental Medicine décrivant les progrès dans la découverte de médicaments ...

Canada articles and careers information on BioSpace

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry. Revive Therapeutics Announces FDA Acceptance of Meeting Request for ...

Ventus sells its lead drug candidate to Novo Nordisk | BioPharma Dive

The Danish pharma will pay Ventus Therapeutics $70 million upfront for an anti-inflammatory drug. Published Sept. ... The Wall Street Journal She ...

Press Releases - Blogue — BIOQuébec

Ventus Therapeutics, Inc., a biopharmaceutical ... Repare Therapeutics Announces ...

Ex-Purdue exec's new immunology startup launches with $60M

... Ventus Therapeutics. Versant Ventures. Allison DeAngelis. By Allison DeAngelis – Life Sciences Reporter, Boston Business Journal. May 6, 2020.

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

"We are pleased with the results of this trial in which VENT-02 demonstrated a broad therapeutic index and complete target coverage, ...

Business Wire – Page 525 – The AI Journal

The AI Journal ... Press release · Gossamer Bio Announces Publication ... Read more. Press Release. May 3, 2024 0 · Press release · Ventus Therapeutics Announces ...